60 plus varieties have been listed 240 plus varieties in the research antidepressant drug development hot!

Text . . . Drug-mad depression, which has developed into a common disease in the world, has the characteristics of high prevalence, high suicide rate and heavy burden of disease, and is the third largest burden of disease among adolescents, while suicide is also the second largest cause of death among 15-29 year olds.
drug treatment, depression is one of the important control means, the current clinical use of most antidepressant drug action mechanism is based on the regulation of monoamine-type delivery system, that is, by regulating 5-HT, NE, DA and other delivery levels to alleviate depressive symptoms, but the residual symptoms associated with drug treatment often lead to repeated episodes of the disease, so more safe and effective antidepressants are still clinically urgent! The concepts of depression commonly used in the clinical use of depression definitions and clinical manifestations and recommended drugs include "depressive mood," "depressive state," and "depressive disorder."
"depressive mood" can be a normal physiological process, short duration, do not need medical treatment, "depressive state" is a group of significant depressive mood as the main characteristics of the syndrome, often manifested as pathological mood, behavior and physical symptoms, the duration of physiological depression is slightly longer, need medical treatment "Depression disorder", which refers to "depression" in psychotherapy, refers to a type of mood disorder caused by various causes, with significant and persistent depression as the main characteristic, with a duration of >2 weeks, which has a significant impact on the social function of patients, meets clinical diagnostic standards and requires active treatment.
PS: Diagnostic criteria for depressive disorder are primarily referred to in The Diagnostic and Statistical Manual of Mental Disorders 5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5).
Photo Source: Lack of Energy, Fatigue, Loss of Appetite, Gastrointestinal Dysfunction, Weight Loss, Insomnia, Pain, Body Discomfort, Sexual Decline, Face Distress, Sighing, Emotional Vulnerability, Speech Reduction, Speed Slowness, slow response, difficulty concentrating; patients who are consciously unhappy, unhappy, no longer interested in things and activities they liked in the past, lose confidence in the future, pessimistic disappointment, low self-evaluation, inferiority, negative thoughts or behaviors, etc. These are the main clinical manifestations of depression.
And for depression, there are nearly 60-70 drug varieties currently on the market worldwide, but the main clinically recommended and commonly used varieties are: SSRIs in the category of SSRIs, citrusin, espressoplan, flusitin, parositin, fluoroxicin; Oxytocin; methocin in the NaSSA category; tricyclycline and tetracycline antidepressants amitrilin, ketamine; monoamine oxidase inhibitor chlorbeamine; 5-serotonin inhibitor/reuptake inhibitor quercetone; melatonin-subject agoraltatin, etc.
The world has entered the NDA stage of antidepressant new drug species although, the world has been listed 60-70 antidepressant varieties, but there is still a steady stream of candidate drugs into different stages of clinical research, rough statistics are currently in the "clinical phase I to NDA stage" of about >240 varieties, see the hot degree of drug development in this field! NDA stage drugs, arguably the most high-rated pre-market development stage, and the current global antidepressant varieties have entered the NDA stage of the drug mainly 5, including 3 single drugs and 2 compound.
single drug species are Clovoxamine, BMS and GSK and Fabre-Kramer, and Novartis' left propylene;
mainly focus on severe depression.
Table 2.1 The world has entered the NDA stage of the new antidepressant drug species worldwide has entered the clinical phase III of the new antidepressant drug species has entered the clinical phase III of the new drug species worldwide has entered the clinical phase III development of the variety, the number of nearly 30, but there have been a number of varieties in the development of the end; To Phase III, Mercadon has 2 varieties into Clinical Phase III, after which some large pharmaceutical companies such as GSK, Novartis, Jansen, Novartis, AbbVie, Tianbian Mitsubishi and so on have products online;
Table 3.1 Globally into the clinical phase III of antidepressants new drugs domestic drug companies antidepressants clinical research new drug types in China's domestic pharmaceutical enterprises, the current clinical research in the field of antidepressants in the new drugs are mainly 8.
As mentioned above, an Ansofaxine (Ansofaxine) of Green leaf pharmaceutical, a 5-serotonin-dephetamine-dopamine triple ingestion inhibitor (SNDRI) intended to be used to treat severe depression; 01, Huahai Pharmaceuticals and Poisons Jointly developed hydrochloric acid oxycodone (the first approved clinical SPARI class chemicals 1 class of antidepressants);
details can be found in the table below.
table 4.1 Domestic pharmaceutical companies antidepressants clinical research new drug reference source: 1. China depression official website 2. WHO official website 3. Psychology space official website 4.Pharmaproject official website 5. Major pharmaceutical companies official website and annual report 6.CNKI data.